H-E-B Updates OTC Sennosides Label for Maximum-Strength Constipation Relief
DailyMed’s October 13, 2026 label update for H-E-B’s maximum-strength sennosides tablet brings a familiar stimulant laxative back into focus with unusually precise consumer-facing instructions. Each film-coated tablet contains sennosides USP, 25 mg, an oral stimulant laxative intended to relieve occasional constipation and generally produce a bowel movement within 6 to 12 hours. The label positions the product squarely in the self-care category, but the wording leaves little room for casual use: the directions, warnings, and time limits are all designed to keep constipation treatment short, deliberate, and alert to red flags.
A stimulant laxative acts differently from fiber or osmotic agents. Sennosides stimulate colonic motility, which is why the onset is typically measured in hours rather than days. For patients who are uncomfortable, traveling, or facing short-lived constipation related to diet or routine disruption, that speed can be useful. For patients with abdominal pain, nausea, vomiting, rectal bleeding, or a change in bowel habits that persists, the same rapid action can obscure a more serious problem if the symptom pattern is dismissed as routine constipation.
The product is marketed as a blue, round, film-coated tablet with imprint code L7 and no score, packaged in blister format. One carton contains 12 tablets, while the larger package contains 15 tablets. The label identifies H E B as the labeler and LNK International, Inc. as the manufacturing and packaging establishment, with marketing information classified under the OTC monograph pathway. Those details matter because OTC laxatives often move through the system as routine shelf products, yet their label language still serves as the main safety barrier between self-treatment and inappropriate repeated use.
Dosing Limits and the Short Window for Self-Treatment
The dosing instructions are straightforward. Adults and children 12 years and older may take 2 tablets once or twice daily. Children 6 to under 12 years may take 1 tablet once or twice daily. Children under 6 years are directed to ask a doctor. Tablets should be swallowed whole with a glass of water and should not be crushed, broken, or chewed. The label also states not to take more than directed.
The strongest practical instruction is time-limited use: do not use for longer than 1 week. In constipation care, duration is often where safety slips. A patient may start with a reasonable over-the-counter choice and then continue it far beyond the intended self-care window, especially if bowel habits remain irregular. A week-long limit forces reassessment rather than endless escalation, which is important because persistent constipation can reflect dehydration, medication effects, reduced mobility, endocrine disease, neurologic dysfunction, or mechanical obstruction.
One sentence on the label carries outsized clinical weight: abdominal pain, nausea, or vomiting should stop casual laxative use unless a physician directs otherwise. Those symptoms raise the possibility that the problem is not simple stool retention. In a patient with true obstruction or another acute abdominal process, increasing colonic propulsion can worsen discomfort and delay appropriate evaluation.
Warning Language Reflects Common Bedside Hazards
The label also instructs patients to ask a doctor before use if they have noticed a sudden change in bowel habits that persists for 2 weeks. That threshold is clinically sensible. A sudden and sustained change in pattern can signal something more than functional constipation, especially when it occurs in an older adult or alongside systemic symptoms. Although the label is brief, the warning points clinicians and consumers toward the same principle: persistent bowel pattern change deserves explanation, not repeated empiricism.
Another warning addresses drug interactions in practical terms. Laxatives may affect how other drugs work, and this product should be taken 2 or more hours before or after other medications. For a stimulant laxative, spacing matters because GI transit can alter absorption timing and complicate therapy for other oral drugs. In real-world practice, this becomes especially relevant for patients already managing multiple medications and trying to self-treat constipation without disrupting the rest of their regimen.
Pregnancy and breast-feeding are handled conservatively on the label: ask a health professional before use. The package also instructs users to keep the product out of the reach of children and to get medical help or contact a Poison Control Center in case of overdose. Those are standard warnings, but in an OTC stimulant product they carry special importance because dosing errors are easy to make when patients confuse occasional relief with routine maintenance therapy.
Product Composition, Packaging, and Consumer Safety Signals
Each tablet contains 35 mg of calcium in addition to the active ingredient. The inactive ingredients include corn starch, dibasic calcium phosphate dihydrate, FD&C Blue No. 1 aluminum lake, hypromellose, magnesium stearate, medium-chain triglycerides, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, silicon dioxide, sodium lauryl sulfate, sucrose, talc, and titanium dioxide. Those components are not therapeutic targets, but they matter in identification, manufacturing consistency, and patient tolerance. The tablet’s visual profile is also documented clearly: blue, round, 10 mm, no score, with imprint L7.
Storage instructions are similarly explicit. The tablets should be stored at 25°C, with permitted excursions between 15° and 30°C. The package is tamper evident, and users are told not to use it if the outer package is opened or the blister is torn or broken. In OTC medicine, packaging integrity is not a cosmetic detail; it is part of the safety chain that reassures the product has not been compromised before it reaches the consumer.
The label’s comparison to ex-lax maximum-strength active ingredient on the principal display panel suggests a familiar retail framing for consumers already accustomed to stimulant laxatives. The phrase “gentle, dependable constipation relief” appears on the display panel, but the rest of the label is more guarded and clinically sober. That tension is typical of OTC laxative marketing: the shelf language promises ease, while the formal instructions insist on restraint, time limits, and review if symptoms do not behave like simple constipation.
In daily practice, the most important issue is not whether sennosides work—they do, and the label makes that clear—but whether the symptom pattern truly fits occasional constipation. A medication that can reliably trigger a bowel movement within hours is useful only when the underlying problem is actually a transient motility issue. When constipation persists, changes abruptly, or arrives with pain, nausea, vomiting, or bleeding, the right next step is no longer self-treatment. It is reassessment, because the label’s warning signs are trying to catch the cases where constipation is only the surface symptom of something more serious.